Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Mostafa Ronaghi, Joseph Garcia, Jock Finlayson, Brook Byers, More

Premium

Mostafa Ronaghi has joined BaseHealth's board of directors.

Ronaghi currently serves as Illumina's chief technology officer and senior vice president. Before joining Illumina, he founded several life sciences companies including ParAllele BioScience, which was acquired by Affymetrix, as well as Avantome and NextBio, both of which were acquired by Illumina. He also previously spent nine years as a principal investigator at the Stanford Genome Technology Center.


Genome British Columbia has appointed Joseph Garcia and Jock Finlayson to its board of directors.

Garcia is a law partner at Blake, Cassels and Graydon, where he practices in the securities and commercial areas for clients in the life sciences and technology sectors, and he is a member of the board of directors of LifeSciences BC.

Finlayson is executive VP and chief policy officer at the Business Council of British Columbia, where he directs the council's work on economic, fiscal, tax, environmental, regulatory, and human capital issues.


Pacific Biosciences' shareholders have re-elected Brook Byers, John Milligan, and Lucy Shapiro to the company's board of directors.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.